disease

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) on Monday revealed results from the Phase 3 IMforte study of Zepzelca (lurbinectedin) in combination with Roche Holdings AG’s (OTC:RHHBY) Tecentriq (atezolizumab) as a first-line maintenance treatment for extensive-stage small cell lung cancer (ES-SCLC...

Trevi Therapeutics, Inc. (NASDAQ:TRVI) revealed topline results on Monday from its Phase 2b CORAL trial of Haduvio for chronic cough in patients with idiopathic pulmonary fibrosis (IPF) (N=165). The primary endpoint in the CORAL trial was achieved, demonstrating statistically...

Bicara Therapeutics Inc. (NASDAQ:BCAX) shares are trading lower Friday following the release of updated interim data from its Phase 1/1b trial of ficerafusp alfa in combination with pembrolizumab for patients with recurrent or metastatic head and neck squamous cell carcinoma. What To know: The...

The Brazilian Health Regulatory Agency (ANVISA) has granted marketing authorization to Valneva SE’s (NASDAQ:VALN) single-dose vaccine Ixchiq for the prevention of disease caused by the chikungunya virus in individuals 18 years of age and older. Chikungunya virus is a mosquito-borne viral...

Tempest Therapeutics, Inc. (NASDAQ:TPST) said on Thursday it had retained MTS Health Partners as a financial advisor. The company plans to explore strategic alternatives to advance its clinical-stage programs and maximize stockholder value. Strategic alternatives may include M&A, partnerships,...

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) on Tuesday revealed 12-month efficacy and safety data from the Phase 2b trial of Descartes-08, lead cell therapy candidate, in participants with generalized myasthenia gravis (MG). MG is a chronic autoimmune disorder that causes muscle weakness and fatigue...

Edgewise Therapeutics, Inc., (NASDAQ:EWTX) on Wednesday reported topline data of EDG-7500 from the Phase 2 CIRRUS-HCM four-week trial in participants with obstructive or nonobstructive Hypertrophic Cardiomyopathy (HCM). HCM is a genetic heart condition where the heart muscle thickens, making...

Vertex Pharmaceuticals Inc (NASDAQ:VRTX) announced on Friday updates about its type 1 diabetes (T1D) portfolio. The company said it would not be advancing further in VX-264 clinical trials. Vertex plans to conduct further analyses, including of explanted devices. Vertex completed enrollment and...

Portage Biotech Inc. (NASDAQ:PRTG) on Thursday presented new preclinical data for PORT-7 (TT-4), a selective Adenosine A2B receptor inhibitor, at the 2025 European Lung Cancer Congress. The new data demonstrate both single-agent activity for PORT-7 and a dramatic >90% inhibition of tumor...

The U.S. Food and Drug Administration has approved Exelixis Inc.’s (NASDAQ:EXEL) Cabometyx (cabozantinib) for two indications in adult and pediatric patients with previously treated, unresectable, locally advanced or metastatic, well-differentiated pancreatic and extra-pancreatic...

Stifel initiated coverage on Monday on Crinetics Pharmaceuticals Inc (NASDAQ:CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors. Crinetics’ lead development...

Johnson & Johnson (NYSE:JNJ) just hit a Golden Cross, a classic bullish technical pattern that signals potential long-term upside. The stock's 50-day simple moving average crossed above its 200-day simple moving average, often seen as a sign of strengthening momentum. While the charts suggest...

Regenxbio Inc (NASDAQ:RGNX) revealed on Wednesday new interim data from two additional patients in the Phase 1/2 portion of the AFFINITY DUCHENNE trial of RGX-202, an investigational gene therapy for Duchenne muscular dystrophy. Results were presented at the 2025 Muscular Dystrophy Association (MDA...

AbbVie Inc (NYSE:ABBV) released on Saturday the final analysis of the confirmatory Phase 3 MIRASOL trial of Elahere (mirvetuximab soravtansine-gynx) in women with folate receptor alpha (FRα)-positive platinum-resistant ovarian cancer (PROC) compared to chemotherapy. The U.S. Food and Drug...

Avidity Biosciences, Inc. (NASDAQ:RNA) released on Monday del-zota topline data from the Phase 1/2 EXPLORE44 trial in people living with Duchenne muscular dystrophy amenable to exon 44 skipping (DMD44). Del-zota is designed to deliver phosphorodiamidate morpholino oligomers (PMOs) to skeletal and...